Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
This review provides an overview of non-small cell lung cancer (NSCLC), focusing on the therapeutic role of antibody-drug conjugates (ADCs), especially trastuzumab deruxtecan (T-DXd) in HER2-mutant metastatic NSCLC.
T-DXd, approved as a second-line treatment, has shown significant clinical benefits including:
- High objective response rates
- Strong disease control rates in key trials
While generally tolerable, interstitial lung disease remains a notable adverse event. Improved safety has been observed with the 5.4 mg/kg dose compared to the 6.4 mg/kg dose.
Multidisciplinary approaches are recommended for managing adverse events.
Ongoing studies are exploring T-DXd in combination with immunotherapy and targeted agents to improve efficacy and safety in high-risk NSCLC patients.